167638-32-6

Basic information

• Product Name: di-tert-butyl 2,2'-(1,2-phenylenebis(oxy))diacetate
• Synonyms: di-tert-butyl 2,2'-(1,2-phenylenebis(oxy))diacetate
• CAS NO: 167638-32-6
• Molecular Weight: 338.401
• Mol File: 167638-32-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: di-tert-butyl 2,2'-(1,2-phenylenebis(oxy))diacetate(CAS DataBase Reference)
• NIST Chemistry Reference: di-tert-butyl 2,2'-(1,2-phenylenebis(oxy))diacetate(167638-32-6)
• EPA Substance Registry System: di-tert-butyl 2,2'-(1,2-phenylenebis(oxy))diacetate(167638-32-6)

Safety Data

• Hazardous Substances Data: 167638-32-6(Hazardous Substances Data)

Upstream product

• 5292-43-3 bromoacetic acid tert-butyl ester 
• 120-80-9 benzene-1,2-diol 

Downstream Products

• 31250-18-7 cryptand 222B 
• 5411-14-3 2-[2-(2-hydroxy-2-oxoethoxy)phenoxy]acetic acid 
• 734513-28-1 1,2-bis--benzene 
• 136383-33-0 1,2-bis(2’-bromoethyl)phenyl ether 
• 10234-40-9 2,2'-(1,2-phenylenedioxy)diethanol 

Relevant articles and documents

Synthesis and Evaluation of Bifunctional [2.2.2]-Cryptands for Nuclear Medicine Applications

For the first time, synthesis of bifunctional [2.2.2]-cryptands (CRYPT) and demonstration of radiolabeling with lead(II) (Pb2+) isotopes are disclosed herein. The synthesis is convenient and high-yielding and gives access to three distinct bifunctional handles (azide (-N3), isothiocyanate (-NCS), and tetrazine (-Tz)) that can enable the construction of radioimmunoconjugates for targeted and pretargeted therapy. Proof-of-principle CRYPT radiolabeling was successful with lead-203 ([203Pb]Pb2+) and demonstrated complexation efficiency superior to that of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and efficiency comparable to that of the current industry standard TCMC (1,4,7,10-tetraaza-1,4,7,10-tetra-(2-carbamoylmethyl)-cyclododecane). In vitro human serum stability assays demonstrated excellent [203Pb]Pb-CRYPT stability over 72 h (91.7 ± 0.56%; n = 3). [203Pb]Pb-CRYPT-radioimmunoconjugates were synthesized from the corresponding CRYPT-immunoconjugate or by conjugating [203Pb]Pb-Tz-CRYPT to transcyclooctene modified trastuzumab (TCO-trastuzumab) via the inverse electron-demand Diels-Alder (IEEDA) reaction. This investigation reveals the potential for CRYPT ligands to become new industry standards for therapeutic and diagnostic radiometals in radiopharmaceutical elaboration.

Quaternary ammonium groups are not crucial for the allosteric effect of gallamine on the human m2 muscarinic receptor.

-